{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:12:34Z","timestamp":1772820754156,"version":"3.50.1"},"reference-count":112,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1053\/j.seminhematol.2009.01.004","type":"journal-article","created":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T04:17:47Z","timestamp":1240373867000},"page":"143-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Treatment of Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1053","volume":"46","author":[{"given":"Efstathios","family":"Kastritis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2009.01.004_bib1","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/0003-4819-105-1-8","article-title":"High-dose glucocorticoid treatment of resistant myeloma","volume":"105","author":"Alexanian","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib3","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1053\/j.seminhematol.2009.01.004_bib4","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.1200\/jco.2006.24.18_suppl.7521","article-title":"Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009) [abstract]","volume":"24","author":"Weber","year":"2006","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib5","first-page":"6","article-title":"Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010) [abstract]","volume":"106","author":"Dimopoulos","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib6","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib7","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2009.01.004_bib8","first-page":"2115","article-title":"A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma","volume":"9","author":"Gertz","year":"1995","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","article-title":"Effective treatment of advanced multiple myeloma refractory to alkylating agents","volume":"310","author":"Barlogie","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2141.1989.tb06269.x","article-title":"VAD chemotherapy for refractory multiple myeloma","volume":"71","author":"Lokhorst","year":"1989","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/bjc.1995.65","article-title":"VAD chemotherapy as remission induction for multiple myeloma","volume":"71","author":"Anderson","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3109\/10428199509056859","article-title":"A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma","volume":"17","author":"Phillips","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00000421-199512000-00003","article-title":"Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma","volume":"18","author":"Gertz","year":"1995","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0140-6736(92)90004-M","article-title":"Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis","volume":"339","author":"MacLennan","year":"1992","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib15","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.1986.4.8.1227","article-title":"Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study","volume":"4","author":"Durie","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/(SICI)1096-8652(200003)63:3<125::AID-AJH3>3.0.CO;2-S","article-title":"Cyclophosphamide, etoposide, vincristine, Adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol","volume":"63","author":"Giles","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib17","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2003.01.055","article-title":"DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma","volume":"21","author":"Lee","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.4065\/81.7.889","article-title":"Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma","volume":"81","author":"Hussein","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/annonc\/mdh026","article-title":"Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study","volume":"15","author":"Zervas","year":"2004","journal-title":"Ann Oncol"},{"issue":"suppl 3","key":"10.1053\/j.seminhematol.2009.01.004_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1634\/theoncologist.8-suppl_3-39","article-title":"Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide","volume":"8","author":"Hussein","year":"2003","journal-title":"Oncologist"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib21","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdl313","article-title":"Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy","volume":"17","author":"Baz","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib22","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2004-07-2911","article-title":"Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies","volume":"105","author":"Orlowski","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00277-006-0220-3","article-title":"Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin","volume":"86","author":"Biehn","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib24","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood.V67.5.1298.1298","article-title":"High-dose melphalan with autologous bone marrow transplantation for multiple myeloma","volume":"67","author":"Barlogie","year":"1986","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib25","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.V70.3.869.869","article-title":"High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma","volume":"70","author":"Barlogie","year":"1987","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib26","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood.V82.8.2324.bloodjournal8282324","article-title":"Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma","volume":"82","author":"Dimopoulos","year":"1993","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib27","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1182\/blood.V84.3.950.950","article-title":"High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants","volume":"84","author":"Vesole","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib28","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1182\/blood.V83.2.512.512","article-title":"Limited value of myeloablative therapy for late multiple myeloma","volume":"83","author":"Alexanian","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib29","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/blood.V84.12.4278.bloodjournal84124278","article-title":"Early myeloablative therapy for multiple myeloma","volume":"84","author":"Alexanian","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bmt.1704545","article-title":"High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy","volume":"34","author":"Kumar","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1046\/j.1365-2141.2003.04646.x","article-title":"Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience","volume":"123","author":"Fassas","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib32","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.bmt.1703715","article-title":"Transplantation as salvage therapy for high-risk patients with myeloma in relapse","volume":"30","author":"Lee","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib33","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment?","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib34","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1182\/blood-2006-07-036848","article-title":"Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning","volume":"109","author":"Crawley","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib35","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0301-472X(02)01010-X","article-title":"Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning","volume":"31","author":"Lee","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.bmt.1703652","article-title":"Fludarabine\/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma","volume":"30","author":"Giralt","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib38","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1365-2141.2003.04299.x","article-title":"Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning","volume":"121","author":"Einsele","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib39","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/cncr.21700","article-title":"Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma","volume":"106","author":"Qazilbash","year":"2006","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib40","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbmt.2004.06.002","article-title":"Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan\/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma","volume":"10","author":"Kroger","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 4","key":"10.1053\/j.seminhematol.2009.01.004_bib41","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminhematol.2005.10.001","article-title":"Lenalidomide and thalidomide: mechanisms of action\u2014similarities and differences","volume":"42","author":"Anderson","year":"2005","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib42","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib43","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib44","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1182\/blood-2008-02-140954","article-title":"First thalidomide clinical trial in multiple myeloma: a decade","volume":"112","author":"van Rhee","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib45","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1365-2141.2005.05914.x","article-title":"A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma","volume":"132","author":"Glasmacher","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib46","first-page":"3377","article-title":"Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma","volume":"8","author":"Neben","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.thj.6200175","article-title":"Thalidomide in patients with advanced multiple myeloma: a study of 83 patients\u2014report of the Intergroupe Francophone du Myelome (IFM)","volume":"3","author":"Yakoub-Agha","year":"2002","journal-title":"Hematol J"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib48","first-page":"689","article-title":"Thalidomide (Thal) in the treatement of advanced multiple myeloma (MM)","volume":"98","author":"Grosbois","year":"2001","journal-title":"Blood"},{"issue":"suppl","key":"10.1053\/j.seminhematol.2009.01.004_bib49","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1200\/jco.2006.24.18_suppl.7520","article-title":"A multicenter prospective randomized study testing non-inferiority of thalidomide 100 mg\/day as compared with 400 mg\/day in patients with refractory\/relapsed multiple myeloma: results of the final analysis of the IFM 01-02 study [abstract]","volume":"24","author":"Yakoub-Agha","year":"2006","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib50","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib51","first-page":"604a","article-title":"Thalidomide alone or with dexamethasone for multiple myeloma [abstract]","volume":"94","author":"Weber","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib52","first-page":"399","article-title":"Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma","volume":"86","author":"Palumbo","year":"2001","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib53","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1023\/A:1011132808904","article-title":"Thalidomide and dexamethasone combination for refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib54","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.2003.04345.x","article-title":"Thalidomide and dexamethasone for resistant multiple myeloma","volume":"121","author":"Anagnostopoulos","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib55","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/sj.thj.6200403","article-title":"Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma","volume":"5","author":"Palumbo","year":"2004","journal-title":"Hematol J"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib56","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1600-0609.2005.00533.x","article-title":"Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant","volume":"75","author":"Palumbo","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib57","first-page":"3563","article-title":"A randomized comparison of dexamethasone + thalidomide (Dex\/Thal) vs Dex + placebo (Dex\/P) in patients (pts) with relapsing multiple myeloma (MM) [abstract]","volume":"108","author":"Fermand","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib58","first-page":"5125","article-title":"Thalidomide in relapsed or refractory patients with multiple myeloma: monotherapy or combination therapy?","volume":"106","author":"Glasmacher","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib59","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib60","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1067\/mjd.2003.87","article-title":"Dermatologic side effects of thalidomide in patients with multiple myeloma","volume":"48","author":"Hall","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"suppl 4","key":"10.1053\/j.seminhematol.2009.01.004_bib61","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/j.seminhematol.2003.09.005","article-title":"Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience","volume":"40","author":"Barlogie","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib62","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1182\/blood.V98.13.3846","article-title":"Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy","volume":"98","author":"Moehler","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib63","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1365-2141.2003.04473.x","article-title":"Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma","volume":"122","author":"Kropff","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib64","first-page":"133","article-title":"Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed\/refractory multiple myeloma: a prospective, multicenter, phase II study","volume":"91","author":"Offidani","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib65","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3816\/CLM.2003.n.011","article-title":"Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival","volume":"4","author":"Zangari","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib66","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.leu.2403322","article-title":"The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed\/refractory multiple myeloma","volume":"18","author":"Garcia-Sanz","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib67","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2141.2005.05521.x","article-title":"Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma","volume":"129","author":"Kyriakou","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib68","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/sj.thj.6200326","article-title":"Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma","volume":"5","author":"Dimopoulos","year":"2004","journal-title":"Hematol J"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib69","first-page":"775a","article-title":"Results of a phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT) [abstract 3226]","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib70","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib71","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib72","first-page":"1565","article-title":"A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; preliminary results [abstract]","volume":"106","author":"Richardson","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib73","first-page":"3597","article-title":"Lenalidomide overcomes poor prognosis conferred by del13q and t(4;14) but not del17p13 in multiple myeloma: results of the Canadian MM016 trial [abstract]","volume":"110","author":"Bahlis","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib74","first-page":"3548","article-title":"Use of Lenalidomide (revlimid +\/- corticosteroids in relapsed\/refractory multiple myeloma patients with elevated baseline serum creatinine levels","volume":"108","author":"Reece","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib75","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/0091270007309563","article-title":"Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis","volume":"47","author":"Chen","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"suppl","key":"10.1053\/j.seminhematol.2009.01.004_bib76","doi-asserted-by":"crossref","first-page":"LBA8025","DOI":"10.1200\/jco.2007.25.18_suppl.lba8025","article-title":"Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]","volume":"25","author":"Rajkumar","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib77","first-page":"2712","article-title":"Dexamethasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed\/refractory multiple myeloma who are treated with lenalidomide\/dexamethasone (MM009\/010 sub-analysis) [analysis]","volume":"110","author":"Miguel","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib78","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib79","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib80","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib81","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib82","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/cncr.21427","article-title":"Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma","volume":"104","author":"Berenson","year":"2005","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib83","first-page":"2720","article-title":"Bortezomib retreatment in relapsed multiple mycelia - a retrospective multicenter survey [abstract]","volume":"110","author":"Hrusovsky","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib84","first-page":"3532","article-title":"Utility of bortezomib retreatment for patients with relapsed multiple myeloma [abstract]","volume":"108","author":"Wolf","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib85","first-page":"3531","article-title":"An observational, retrospective analysis of retreatment with bortezomib of mulitple myeloma (MM) patients [abstract]","volume":"108","author":"Conner","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib86","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","article-title":"Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma","volume":"106","author":"Lonial","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib87","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1182\/blood-2006-09-046409","article-title":"Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study","volume":"109","author":"Chanan-Khan","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib88","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/sj.leu.2405087","article-title":"Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study","volume":"22","author":"San-Miguel","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib89","first-page":"2739","article-title":"Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens [abstract]","volume":"110","author":"Roussou","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib90","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib91","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1080\/10428190500097086","article-title":"Velcade, doxil and thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma","volume":"46","author":"Chanan-Khan","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib92","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-2141.2008.07147.x","article-title":"The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma","volume":"141","author":"Ciolli","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib93","first-page":"5087","article-title":"Liposomal doxorubicin (Myocet) enhances the efficacy of bortezomib, dexamethasone plus thalidomide in refractory myeloma [abstract]","volume":"108","author":"Ciolli","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib94","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2005.03.2383","article-title":"Phase I\/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma","volume":"24","author":"Berenson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib95","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00277-008-0501-0","article-title":"Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1\/2 study after longer follow-up","volume":"87","author":"Berenson","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib96","first-page":"2713","article-title":"Bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma: final results of a phase I\/II clinical trial [abstract]","volume":"110","author":"Popat","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib97","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3324\/haematol.11228","article-title":"The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone","volume":"92","author":"Davies","year":"2007","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib98","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.2007.06656.x","article-title":"Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma","volume":"138","author":"Kropff","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib99","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1200\/JCO.2007.14.2372","article-title":"Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma","volume":"26","author":"Reece","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib100","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1080\/10428190701694194","article-title":"Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma","volume":"48","author":"Fenk","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib101","first-page":"4851","article-title":"Combination therapy of bortezomib with bendamustin in elderly patients with advanced multiple myeloma","volume":"110","author":"Hrusovsky","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib102","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib103","first-page":"2552","article-title":"Velcade (V)-thalidomide (T)-dexamethasone (D) for advanced and refractory multiple myeloma (MM): long-term follow-up of phase I-II trial UARK 2001-37: superior outcome in patients with normal cytogenetics and no prior T [abstract]","volume":"106","author":"Zangari","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib104","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1182\/blood-2006-08-042275","article-title":"Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma","volume":"109","author":"Palumbo","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib105","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/leu.2008.235","article-title":"The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed\/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis","volume":"22","author":"Terpos","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib106","first-page":"405","article-title":"Lenalidomide plus bortezomib (Rev-Vel) in relapsed and\/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial [abstract]","volume":"108","author":"Richardson","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib107","first-page":"2714","article-title":"Lenalidomide, bortezomib, and dexamethasone (Rev\/Vel\/Dex) in patients with relapsed or relapsed\/refractory multiple myeloma (MM): preliminary results of a phase II study","volume":"110","author":"Richardson","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib108","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/bmt.2008.180","article-title":"Impact of early relapse after auto-SCT for multiple myeloma","volume":"42","author":"Kumar","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib109","first-page":"3552","article-title":"Lenalidomide in combination with dexamethasone is more effective than dexamethasone at first relapse in relapsed multiple myeloma [abstract]","volume":"108","author":"Stadtmauer","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib110","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2008-02-141614","article-title":"Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib111","first-page":"408","article-title":"Lenalidomide (Revlimid), Adriamycin and dexamethasone chemotherapy (RAD) is safe and effective in treatment of relapsed multiple myeloma\u2014first results of a German multicenter phase I\/II trial","volume":"108","author":"Knop","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2009.01.004_bib112","first-page":"3555","article-title":"Lenolidamide (Revlimid), in combination with cyclophosphamide and dexamethasone (CRD) is an effective regimen for heavily pre-treated myeloma patients [abstract]","volume":"108","author":"Morgan","year":"2006","journal-title":"ASH Annual Meeting Abstracts"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196309000055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196309000055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:19:55Z","timestamp":1758521995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196309000055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":112,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0037196309000055"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2009.01.004","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Relapsed\/Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2009.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}